润达医疗11月20日获融资买入1334.12万元，融资余额6.20亿元

Core Viewpoint - RunDa Medical experienced a decline in stock price and trading volume, indicating potential challenges in its financial performance and market perception [1][2]. Group 1: Financial Performance - As of September 30, 2025, RunDa Medical reported a revenue of 5.268 billion yuan, a year-on-year decrease of 14.70% [2]. - The company recorded a net profit attributable to shareholders of -163 million yuan, representing a significant year-on-year decline of 422.64% [2]. - Cumulative cash dividends since the A-share listing amount to 373 million yuan, with 165 million yuan distributed over the past three years [3]. Group 2: Shareholder and Market Activity - As of November 20, 2023, the total number of shareholders for RunDa Medical was 64,800, a decrease of 1.05% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.06% to 9,317 shares [2]. - The financing balance for RunDa Medical was 620 million yuan, accounting for 6.70% of its market capitalization, which is below the 40th percentile level over the past year, indicating a low financing position [1].